





Fig 1. Flow of information diagram for RCTs included in review






Absolute risk difference for all CINV endpoints

Endpoints	Absolute risk difference (%)	95% confidence interval (%)	Test for overall effect	Heterogeneity test	Satisfies MASCC/ESMO antiemetic guidelines requirement
CR, acute phase	4	1-7	p=0.007	p=0.73	No
CR, delayed phase	9	5-13	p<0.00001	p=0.40	Approaching requirement
CR, overall phase	9	5-13	p<0.00001	p=0.61	Approaching requirement
CC, acute phase	2	-1 to +6	p=0.18	p=0.32	No
CC, delayed phase	8	4-12	p=0.0002	p=0.46	Approaching requirement
CC, overall phase	7	3-11	p=0.002	p=0.41	Approaching requirement
No nausea, acute phase	3	0-6	p=0.02	p=0.63	No
No nausea, delayed phase	7	3-11	p=0.001	p=0.85	Approaching requirement
No nausea, overall phase	6	2-10	p=0.006	p=0.99	Approaching requirement
No vomiting, acute phase	4	1-7	p=0.004	p=0.89	No
No vomiting, delayed phase	13	2-24	p=0.02	p=0.008	Yes
No vomiting, overall phase	14	4-24	p=0.008	p=0.02	Yes

A Efficacy of palonosetron compared with NK₁ RA and palonosetron in the prophylaxis of chemotherapy-induced-nausea and vomiting – complete response in the acute phase **B** Complete response in the delayed phase **C** Complete response in the overall phase






A Efficacy of palonosetron compared with NK₁ RA and palonosetron in the prophylaxis of chemotherapy-induced-nausea and vomiting – no nausea response in the acute phase **B** No nausea in the delayed phase **C** No nausea in the overall phase






We thank the generous support of Bratty Family Fund, Michael and Karyn Goldstein Cancer Research Fund, Joey and Mary Furfari Cancer Research Fund, Pulenzas Cancer Research Fund, Joseph and Silvana Melara Cancer Research Fund, and Ofelia Cancer Research Fund.

A Efficacy of palonosetron compared with NK₁ RA and palonosetron in the prophylaxis of chemotherapy-induced-nausea and vomiting – complete control in the acute phase **B** Complete control in the delayed phase **C** Complete control in the overall phase



A No vomiting response in the acute phase **B** No vomiting in the delayed phase **C** No vomiting in the overall phase



Conclusions

- NK₁RA in combination with PALO is statistically more efficacious than PALO alone

We thank the generous support of Bratty Family Fund, Michael and Karyn Goldstein Cancer Research Fund, Joey and Mary Furfari Cancer Research Fund, Pulenzas Cancer Research Fund, Joseph and Silvana Melara Cancer Research Fund, and Ofelia Cancer Research Fund.